Please use this identifier to cite or link to this item: https://repositorio.udes.edu.co/handle/001/3153
Title: The International Polycap Study-3 (TIPS-3) : Design, baseline characteristics and challenges in conduct
Authors: López Jaramillo, Patricio
Joseph, Philip
Pais, Prem
Dans, Antonio
Bosch, Jackie
Xavier, Denis
Yusoff, Khalid
Santoso, Anwar
Talukder, Shamim
Gamra, Habib
Yeates, Karen
Camacho López, Paul Anthony
Tyrwhitt, Jessica
Gao, Peggy
Teo, Koon
Yusuf, Salim
Keywords: International Polycap Study-3
Challenges in conduct
Issue Date: 2-Aug-2018
Abstract: BACKGROUND: It is hypothesized that in individuals without clinical cardiovascular disease (CVD), but at increased CVD risk, a 50% to 60% reduction in CVD risk could be achieved using fixed dose combination (FDC) therapy (usually comprised of multiple blood-pressure agents and a statin [with or without aspirin]) in a single "polypill". However, the impact of a polypill in preventing clinical CV events has not been evaluated in a large randomized controlled trial. METHODS: TIPS-3 is a 2x2x2 factorial randomized controlled trial that will examine the effect of a FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol, ramipril, hydrochlorothiazide, and a statin) reduces CV events in persons without a history of CVD, but who are at least at intermediate CVD risk. Additional interventions in the factorial design of the study will compare the effect of (1) aspirin versus placebo on CV events (and cancer), (2) vitamin D versus placebo on the risk of fractures, and (3) the combined effect of aspirin and the Polycap on CV events. RESULTS: The study has randomized 5713 participants across 9 countries. Mean age of the study population is 63.9 years, and 53% are female. Mean INTERHEART risk score is 16.8, which is consistent with a study population at intermediate CVD risk. CONCLUSION: Results of the TIP-3 study will be key to determining the appropriateness of FDC therapy as a strategy in the global prevention of CVD.
Description: 8 p.
Source: https://reader.elsevier.com/reader/sd/pii/S0002870318302229?token=5A5E02D67843CA06A31576BF531D6CD2025CB1C8A89928EB526365D92C7B27B0FCCA234A1BFDE6D74D5CBF776C85FBE4
URI: http://repositorio.udes.edu.co/handle/001/3153
ISSN: 1097-6744
0002-8703
Appears in Collections:DCABA. Artículos de Investigación



This item is licensed under a Creative Commons License Creative Commons